- SENIOR FACULTY Medicine, Gastroenterology
Beaudoin M, Goyette P, Boucher G, Lo KS, Rivas MA, Stevens C, Alikashani A, Ladouceur M, Ellinghaus D, Törkvist L, Goel G, Lagacé C, Annese V, Bitton A, Begun J, Brant SR, Bresso F, Cho JH, Duerr RH, Halfvarson J, McGovern DP, Radford-Smith G, Schreiber S, Schumm PL, Sharma Y, Silverberg MS, Weersma RK, D'Amato M, Vermeire S, Franke A, Lettre G, Xavier RJ, Daly MJ, Rioux JD. Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis. PLoS genetics 2013; 9(9).
Beaugerie L, Carrat F, Colombel JF, Bouvier AM, Sokol H, Babouri A, Carbonnel F, Laharie D, Faucheron JL, Simon T, de Gramont A, Peyrin-Biroulet L. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut 2014 Sep; 63(9).
Bernheim O, Colombel JF, Ullman TA, Laharie D, Beaugerie L, Itzkowitz SH. The management of immunosuppression in patients with inflammatory bowel disease and cancer. Gut 2013 Nov; 62(11).
Billioud V, Ford AC, Tedesco ED, Colombel JF, Roblin X, Peyrin-Biroulet L. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. Journal of Crohn's & colitis 2013 Dec; 7(11).
Allen PB, Kamm MA, Peyrin-Biroulet L, Studd C, McDowell C, Allen BC, Connell WR, De Cruz PP, Bell SJ, Elliot RP, Brown S, Desmond PV, Lemann M, Colombel JF. Development and validation of a patient-reported disability measurement tool for patients with inflammatory bowel disease. Alimentary pharmacology & therapeutics 2013 Feb; 37(4).
De Vroey B, Gower-Rousseau C, Colombel JF. Exploring life before IBD. Gut 2013 May; 62(5).
Danese S, Colombel JF, Peyrin-Biroulet L, Rutgeerts P, Reinisch W. Review article: the role of anti-TNF in the management of ulcerative colitis -- past, present and future. Alimentary pharmacology & therapeutics 2013 May; 37(9).
Cosnes J, Bourrier A, Laharie D, Nahon S, Bouhnik Y, Carbonnel F, Allez M, Dupas JL, Reimund JM, Savoye G, Jouet P, Moreau J, Mary JY, Colombel JF. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology 2013 Oct; 145(4).
Colombel JF, Sendid B, Jouault T, Poulain D. Secukinumab failure in Crohn's disease: the yeast connection?. Gut 2013 May; 62(5).
Legraverend JM, Canarelli JP, Boudailliez B, Ricard Y, Collet LM, Bove N. [Cavernous hemangioma of the bladder in children. Apropos of a case]. Annales d'urologie 1986; 20(4).
Bouguen G, Levesque BG, Feagan BG, Kavanaugh A, Peyrin-Biroulet L, Colombel JF, Hanauer SB, Sandborn WJ. Treat to Target: A Proposed New Paradigm for the Management of Crohn's Disease. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2013 Sep;.
Boualit M, Salleron J, Turck D, Fumery M, Savoye G, Dupas JL, Lerebours E, Duhamel A, Merle V, Cortot A, Colombel JF, Peyrin-Biroulet L, Gower-Rousseau C. Long-term outcome after first intestinal resection in pediatric-onset Crohn's disease: a population-based study. Inflammatory bowel diseases 2013 Jan; 19(1).
Gerard R, Sendid B, Colombel JF, Poulain D, Jouault T. An immunological link between Candida albicans colonization and Crohn's disease. Critical reviews in microbiology 2013 Jul;.
Gensollen T, Bourges C, Rihet P, Rostan A, Millet V, Noguchi T, Bourdon V, Sobol H, Dubuquoy L, Bertin B, Fumery M, Desreumaux P, Colombel JF, Chamaillard M, Hebuterne X, Hofman P, Naquet P, Galland F. Functional polymorphisms in the regulatory regions of the VNN1 gene are associated with susceptibility to inflammatory bowel diseases. Inflammatory bowel diseases 2013 Oct; 19(11).
Ferrante M, Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens GR, van der Woude CJ, Danese S, Diamond RH, Oortwijn AF, Tang KL, Miller M, Cornillie F, Rutgeerts PJ. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology 2013 Nov; 145(5).
Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A. Vedolizumab as induction and maintenance therapy for ulcerative colitis. The New England journal of medicine 2013 Aug; 369(8).
Dussault C, Gower-Rousseau C, Salleron J, Vernier-Massouille G, Branche J, Colombel JF, Maunoury V. Small bowel capsule endoscopy for management of Crohn's disease: a retrospective tertiary care centre experience. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2013 Jul; 45(7).
Bell WJ. On being two hundred 1787-1987. Transactions & studies of the College of Physicians of Philadelphia 1987 Mar; 9(1).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Colombel during 2013 and/or 2014. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Abbott Laboratories; Bristol-Myers Squibb; Celgene Corporation; Genentech, Inc.; Giuliani S.p.A.; Hospira, Inc.; Merck & Co., Inc.; Millennium Pharmaceuticals, Inc. (Takeda Pharmaceutical Company Limited ); Nestlé; Pfizer Inc.; Receptos Inc.; Schering-Plough (Merck & Co., Inc.); Teva Pharmaceutical Industries Ltd.; UCB S.A.; sanofi-aventis
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose.
- Abbott Laboratories; Ferring Pharmaceuticals; Merck & Co., Inc.; Schering-Plough (Merck & Co., Inc.)
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Intestinal Biotech Development
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.